Evaluating the benefits of high-dose statin preloading in ST-segment elevation myocardial infarction management: insights from a systematic review and meta-analysis.
Bernardo Resende, Emídio Mata, Tomás Carlos et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed high-dose statin preloading before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). It included nine randomised controlled trials with 1862 patients, comparing preloading with placebo or no statin. Preloading was associated with greater odds of post-PCI TIMI flow grade 3 (OR: 1.52, 95% CI: 1.06-2.20) and lower odds of all-cause mortality (OR: 0.59, 95% CI: 0.36-0.98). The analysis found no significant difference in achieving at least 50% ST-segment resolution.
Key findings
- High-dose statin preloading increased the likelihood of post-PCI TIMI flow grade 3 (OR: 1.52, 95% CI: 1.06-2.20).
- Preloading was associated with lower all-cause mortality (OR: 0.59, 95% CI: 0.36-0.98).
- There was no significant difference in at least 50% ST-segment resolution (OR: 1.04, 95% CI: 0.71-1.50).
Why it matters
The findings suggest that statin loading before primary PCI may be associated with better angiographic reperfusion and lower mortality in STEMI. The absence of a significant difference in ST-segment resolution indicates that the observed benefits were not consistent across reperfusion measures. These pooled trial results provide evidence relevant to ongoing consideration of pre-PCI statin use.